Novadoz Pharmaceuticals to launch first 3 U.S. generics
Novadoz is set to roll out its first three generics in the United States. The Piscataway, N.J.-based U.S. sales and marketing affiliate of Hyderabad, India-based MSN Group received approval for the products in the fall of 2017.
The products it's set to launch are rosuvastatin calcium, a generic of cholesterol-lowering drug Crestor; 400-mg moxifloxacin hydrochloride tablets, a generic of anti-infective Avelox; and breast cancer treatment capecitabine, a generic of Xeloda, in 150- and 500-mg tablets.
“This is a major milestone for MSN Group as we are moving up the value chain," MSN chairman M.S.N. Reddy said. "Based on our vertical integration model, we are hopeful to bring more affordable medicines to the U.S. market in the near future.”
Novadoz president of North America generics, Seshu Akula, said, “The recent approvals for rosuvastatin, capecitabine and moxifloxacin mark a significant event for the commercialization of the MSN Group’s entry into the U.S market with finished dosage forms. Novadoz will benefit from the company’s vertical integration of API and intermediates, expertise in product development and technology, along with the company’s ability to manufacture high barrier of entry products,”
The products it's set to launch are rosuvastatin calcium, a generic of cholesterol-lowering drug Crestor; 400-mg moxifloxacin hydrochloride tablets, a generic of anti-infective Avelox; and breast cancer treatment capecitabine, a generic of Xeloda, in 150- and 500-mg tablets.
“This is a major milestone for MSN Group as we are moving up the value chain," MSN chairman M.S.N. Reddy said. "Based on our vertical integration model, we are hopeful to bring more affordable medicines to the U.S. market in the near future.”
Novadoz president of North America generics, Seshu Akula, said, “The recent approvals for rosuvastatin, capecitabine and moxifloxacin mark a significant event for the commercialization of the MSN Group’s entry into the U.S market with finished dosage forms. Novadoz will benefit from the company’s vertical integration of API and intermediates, expertise in product development and technology, along with the company’s ability to manufacture high barrier of entry products,”